FibroBiologics, Inc. SEC filings FBLG
FibroBiologics, Inc. has 242 filings in SEC EDGAR's recent list, going back to Jan 31, 2023. Its latest annual report, Form ARS, was filed on May 5, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Jul 31, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 8, 2026 (material agreement, new debt, unregistered share sale). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Oct 8, 2026 | Oct 7, 2026 |
| 8-K |
Current report
Shareholder vote results, Regulation FD disclosure
|
Sep 18, 2026 | Sep 17, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Sep 15, 2026 | Sep 15, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Aug 24, 2026 | Aug 20, 2026 |
| 8-K |
Current report
Listing notice
|
Jul 24, 2026 | Jul 22, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jul 9, 2026 | Jul 2, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Jun 29, 2026 | Jun 25, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 23, 2026 | Jun 22, 2026 |
| 8-K |
Current report
Material agreement
|
May 6, 2026 | May 5, 2026 |
| 8-K |
Current report
Officer or director change
|
May 5, 2026 | May 4, 2026 |
| 8-K |
Current report
Material agreement
|
May 1, 2026 | May 1, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 20, 2026 | Mar 9, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Apr 17, 2026 | Apr 16, 2026 |
| 8-K/A |
Amended current report
Material agreement, Agreement ended, Other events
|
Apr 9, 2026 | Apr 3, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Apr 9, 2026 | Apr 3, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Apr 3, 2026 | Mar 30, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Apr 2, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Officer or director change
|
Mar 6, 2026 | Mar 4, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Feb 23, 2026 | Feb 20, 2026 |
| 8-K |
Current report
Listing notice
|
Feb 6, 2026 | Feb 3, 2026 |
| 8-K |
Current report
Listing notice
|
Jan 2, 2026 | Dec 30, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Dec 15, 2025 | Dec 14, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Nov 25, 2025 | Nov 24, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure, Other events
|
Nov 19, 2025 | Nov 18, 2025 |
| 8-K |
Current report
Listing notice
|
Aug 8, 2025 | Aug 4, 2025 |
| 8-K/A |
Amended current report
Unregistered share sale
|
Jul 18, 2025 | Dec 20, 2024 |
| 8-K |
Current report
Unregistered share sale
|
Jul 18, 2025 | Jun 20, 2025 |
| 8-K |
Current report
Listing notice
|
Jul 3, 2025 | Jul 1, 2025 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Regulation FD disclosure
|
Jun 16, 2025 | Jun 16, 2025 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jun 13, 2025 | Jun 12, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jun 9, 2025 | Jun 9, 2025 |
| 8-K |
Current report
Officer or director change
|
May 5, 2025 | May 2, 2025 |
| 8-K |
Current report
Unregistered share sale
|
Feb 7, 2025 | Jan 7, 2025 |
| 8-K |
Current report
Officer or director change
|
Jan 24, 2025 | Jan 23, 2025 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Officer or director change, Regulation FD disclosure
|
Dec 31, 2024 | Dec 27, 2024 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Regulation FD disclosure
|
Dec 23, 2024 | Dec 20, 2024 |
| 8-K |
Current report
Material agreement, Agreement ended, Unregistered share sale
|
Dec 20, 2024 | Dec 19, 2024 |
| 8-K |
Current report
Officer or director change, Other events
|
Oct 29, 2024 | Oct 25, 2024 |
| 8-K |
Current report
Material agreement
|
Sep 24, 2024 | Sep 19, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Aug 28, 2024 | Aug 27, 2024 |
| 8-K |
Current report
Unregistered share sale, Regulation FD disclosure
|
Aug 27, 2024 | Aug 26, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Jun 27, 2024 | Jun 25, 2024 |
| 8-K |
Current report
Other events
|
Apr 26, 2024 | Apr 26, 2024 |
| 8-K |
Current report
Other events
|
Feb 20, 2024 | Feb 20, 2024 |
| 8-K |
Current report
Other events
|
Feb 14, 2024 | Feb 13, 2024 |
| 8-K |
Current report
Other events
|
Feb 8, 2024 | Feb 8, 2024 |
| 8-K |
Current report
Other events
|
Feb 6, 2024 | Feb 6, 2024 |
| 8-K |
Current report
Other events
|
Feb 2, 2024 | Jan 31, 2024 |
Showing 48 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- FBLG (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Houston, TX
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1958777
- Former names
- FibroBiologics Inc. (until Feb 6, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.